C-type natriuretic peptide analogue increases growth velocity in children with achondroplasia
Daily treatment with subcutaneous vosoritide leads to a sustained increase in annualised growth velocity, with generally mild side effects, in children with achondroplasia, show data published in The New England Journal of Medicine.